Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity
Journal of Cellular Physiology · 2026
DOI: 10.1002/jcp.70237 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Physiology, 2026. Verfasst von Abaher O Altamimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Ferroptosis, Colorectal Neoplasms. Die Arbeit nennt 159 Literaturangaben. Gefördert von: University of Sharjah.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a global health concern and a leading cause of cancer mortality, where therapeutic resistance persists as the central barrier to sustained response. Most conventional therapies rely on apoptosis, but CRC frequently resists through p53 alterations, anti‐apoptotic BCL‐2 upregulation, and drug efflux mechanisms. Here, we explore unconventional cell death pathways, focusing on ferroptosis, as a strategy to overcome apoptosis‐dependent therapeutic resistance in CRC. We discussed the molecular mechanisms of ferroptosis, including GPX4 blockade, iron dysregulation, and lipid metabolism remodeling, and emphasized their implications for drug‐resistant CRC. Then, necroptosis, pyroptosis, and autophagy were discussed in relation to their crosstalk with ferroptosis. Preclinical models show that ferroptosis inducers (e.g., erastin, RSL3, talaroconvolutin) selectively kill chemoresistant CRC, including KRAS‐mutant CRC, and potentiate the efficacy of conventional regimens. The therapeutic duality of autophagy, pyroptosis, and necroptosis in CRC is discussed, with emphasis on ferroptosis's ability to circumvent traditional mechanisms of resistance. Yet, clinical translation is hindered by insufficient pharmacokinetics, systemic toxicity, limited biomarker availability, tumor heterogeneity, compensatory antioxidant pathways, and the need for safer delivery platforms. We propose that ferroptosis is most likely to enter CRC therapy through rational combinations, biomarker‐guided patient selection, and tumor‐targeted delivery platforms rather than as a stand‐alone cytotoxic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
- Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, Ohio, USA.
- Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
ORCID-Profile: Abaher O Altamimi, Noha M Elemam, Iman M Talaat
Förderung
- University of Sharjah
Zitieren
APA
Altamimi, A. O., Elemam, N. M., Kalady, M. F., & Talaat, I. M. (2026). Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.70237
Vancouver
Altamimi AO, Elemam NM, Kalady MF, Talaat IM. Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity. Journal of Cellular Physiology. 2026. doi:10.1002/jcp.70237
BibTeX
@article{Altamimi2026,
author = {Altamimi, Abaher O and Elemam, Noha M and Kalady, Matthew F and Talaat, Iman M},
title = {Revisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity},
journal = {Journal of Cellular Physiology},
year = {2026},
doi = {10.1002/jcp.70237}
}
EUVIMED